Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intratumoral Cisplatin for Early Stage NSCLC
NCT04809103Phase 1Completed
- Sponsor
- The University of Vermont
- Start
- Mar 2021
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of cisplatin in non-small cell lung cancer (NSCLC) (2 arms), sponsored by The University of Vermont. Primary endpoint: Dose Limiting Toxicity at 2 weeks. Started Mar 2021; status: completed.
02
Drugs
cisplatin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04809103.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04809103.